Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safet...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Colecção: | Hematology/Oncology and Stem Cell Therapy |
| Assuntos: | |
| Acesso em linha: | https://journals.lww.com/10.56875/2589-0646.1039 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|